Asia-Pacific Companion Diagnostics Market was worth USD 0.63 million in 2018 and estimated to be growing at a CAGR of 24.73%, to reach USD 1.89 million by 2023 Asia-Pacific ranks as the fastest growing market over the forecast period. Growth in the region is favoured by increasing population, increased spending on healthcare R&D by government and growing base of affluent middle class population.
Companion diagnostics are diagnostic tests used to increase effectiveness of the drug and for pre-determining the efficacy of the treatment. These products are mainly in-vitro devices or imaging tools, which are either developed after the drug is in the market or during drug development. Benefits provided by these products are providing crucial information on an individual’s risk factors for chronic conditions and enables health care professionals to decide whether drug it more beneficial over its risks or not.
Companion diagnostics have accompanied the development of personalized medicine, an advance approach in the clinical treatment process. Key factors driving the companion diagnostics market are accelerated drug regulatory approvals, merging new pharmaceuticals and diagnostics, improved efficacy profile of drugs and reduced healthcare expenditure. Complex clinical trial procedures are hindering the market growth.
The Asia-pacific clinical nutrition market is segmented on the basis of indication into Oncology (Colorectal Cancer, Breast Cancer, Lung Cancer, Melanoma, and Gastric Cancer), Cardiovascular Diseases, Central Nervous System Disorders, Inflammation and Virology Diseases. Further, Oncology is sub-segmented as Colorectal Cancer, Breast Cancer, Lung Cancer, Melanoma, and Gastric Cancer. Oncology being the highest revenue creating segment as most of the companion diagnostics has been developed to detect one or the other cancer biomarkers. On the basis of technology, the market is bifurcated into Immunohistochemistry and molecular diagnostics. Molecular diagnostics is segmented into in-situ hybridization, real time PCR and gene sequencing.
Based on geography the Asia-Pacific market is analysed under various regions namely, China, India, Japan, South Korea and Australia. Due to rapid increase in population in developing countries like China and India are the fastest growing markets in this region.
Some of the key participating global players in companion diagnostics market global market are Abbott Molecular Inc., Roche Molecular Systems Inc., Leica Biosystems Nussloch GmbH, bioMérieux Inc., Dako Inc., Qiagen Ltd., ARUP Laboratories, Myriad Genetics Inc.,Biogenex Laboratories Inc., Ventana Medical Systems Inc., Thermo Fisher Scientific Inc. and others.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Indications
5.1.1 Oncology
5.1.1.1 Colorectal Cancer
5.1.1.2 Breast Cancer
5.1.1.3 Lung Cancer
5.1.1.4 Gastric Cancer
5.1.1.5 Melanoma
5.1.2 Inflammation and Autoimmune Diseases
5.1.3 Cardiovascular Diseases
5.1.4 Central Nervous System Disorders
5.1.5 Virology Diseases
5.2 By Technology
5.2.1 Immuno Histochemistry
5.2.2 Molecular Diagnostics
5.2.2.1 In-Situ Hybridization
5.2.2.2 Real Time PCR
5.2.2.3 Gene Sequencing
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Molecular Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Roche Molecular Systems Inc.
8.3 Leica Biosystems Nussloch GmbH
8.4 BioMérieux Inc.
8.5 Dako Inc.
8.6 Qiagen Ltd.
8.7 ARUP Laboratories
8.8 Myriad Genetics Inc.
8.9 Biogenex Laboratories, Inc.
8.10 Ventana Medical Systems Inc.
8.11 Thermo Fisher Scientific Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
